Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

There are conflicting data regarding the effects of TK inhibitors on tumor immunity ... The study of imatinib and sorafenib would be insufficient to conclude an overall estimation.

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Although we predict that protein tyrosine kinase inhibitors such as the second generation inhibitors nilotinib and dasatinib will significantly inhibit the progression of disease in patients with ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

4 Other frontline options are durvalumab (Imfinzi; AstraZeneca) plus tremelimumab-actl (Imjudo; AstraZeneca) and the single-agent tyrosine kinase inhibitors (TKIs) sorafenib (Nexavar; Bayer ...